BioCryst Pharmaceuticals, Inc. (BCRX) Position Raised by Artal Group S.A.

Artal Group S.A. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 70.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 850,000 shares of the biotechnology company’s stock after purchasing an additional 350,000 shares during the period. Artal Group S.A. owned 1.06% of BioCryst Pharmaceuticals worth $4,726,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in BioCryst Pharmaceuticals by 0.3% during the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 45 shares in the last quarter. Legal & General Group Plc raised its holdings in BioCryst Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in BioCryst Pharmaceuticals during the second quarter worth approximately $126,000. Bank of America Corp DE raised its holdings in BioCryst Pharmaceuticals by 43.3% during the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 7,568 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in BioCryst Pharmaceuticals by 4.7% during the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,500 shares in the last quarter. 85.80% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals, Inc. (NASDAQ BCRX) traded down 1.11% on Tuesday, reaching $5.36. 358,191 shares of the company’s stock traded hands. The firm’s market capitalization is $431.09 million. The firm’s 50 day moving average price is $4.86 and its 200 day moving average price is $6.07. BioCryst Pharmaceuticals, Inc. has a 52-week low of $3.75 and a 52-week high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) earnings per share. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.75) EPS for the current fiscal year.

Several equities research analysts recently commented on BCRX shares. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Wednesday, August 9th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Jefferies Group LLC raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $5.00 to $7.00 in a report on Wednesday, September 6th. Finally, ValuEngine raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.78.

ILLEGAL ACTIVITY NOTICE: This story was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://stocknewstimes.com/2017/09/19/biocryst-pharmaceuticals-inc-bcrx-position-raised-by-artal-group-s-a.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply